Navigation Links
PINC trial launched to test new treatment for pre-invasive breast cancer
Date:3/2/2010

FAIRFAX, Va.Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

In January, the IBCI and CAPMM launched the PINC Trial, short for Preventing Invasive Breast Neoplasia with Chloroquine. This three-year clinical trial will test the effectiveness of the anti-malarial drug chloroquine in treating 90 women with ductal carcinoma in situ (DCIS), a type of breast cancer in which the cancer cells start in the milk ducts but have not yet become invasive and spread in the breast. Once the cancer cells start to spread in the breast and throughout the body, the condition is considered invasive and can often be fatal.

With an estimated 254,650 patients diagnosed in 2009 alone, breast cancer is the most common form of cancer in women according to statistics by the American Cancer Society. Approximately one quarter of those patients will have DCIS. Many more women are being diagnosed with DCIS, non-invasive breast cancer, with the routine use of screening mammography.

According to Kirsten Edmiston, MD, the trial's principal investigator and medical director of cancer services at Inova Health System, the trial is designed to prevent breast cancer cells from becoming deadly by killing pre-invasive cancer cells using a novel therapy with chloroquine, which has been used to treat malaria in the past.

"We have identified a particular cellular process called autophagy that is very involved in the survival of DCIS. In pre-clinical work, our team found that if we block autophagy in DCIS cells with chloroquine, that it kills the cells so that they're not able to become invasive," says Edmiston. "What this trial is proposing is to treat DCIS patients with chloroquine, an autophagy blocker before they receive standard of care surgery to treat their DCIS disease. We believe that the treatment will kill the DCIS cells before they become invasive and shrink the size of the DCIS. We may be able to prevent someone from needing a mastectomy and offer them breast conserving surgery."

Once patients have consented and enrolled, the size of their breast tumor will be measured through a non-invasive imaging technique called magnetic resonance imaging (MRI). Tissue samples will be taken from patients by Inova's doctors and transported to CAPMM for analysis. The PINC trial will combine chloroquine with Tamoxifen depending on the patient's tumor profile. After treatment, the MRI will be repeated to see if the tumor has shrunk and the patient will then proceed with surgery and follow up therapy.

What made the researchers think to use a malaria drug to treat breast cancer? According to Ginny Espina, a CAPMM research assistant professor, it works by starving the cancerous cells.

"Pre-cancerous cells have adapted to survive inside the milk duct without a blood supply and with very few nutrients. They overcome starvation through a process called autophagy. It's a way for a cell to make its own food and store it in a 'cookie jar.' In the breast ducts, the DCIS cells use these 'cookies' to survive and potentially spread. Simply put, chloroquine goes into the cell's 'cookie jars' and prevents the cells from using that food so that they eventually die from starvation," says Espina.

Of note, researchers are also using chloroquine in patients with unique types of brain tumors.

The treatment of DCIS is controversial because most DCIS lesions remain dormant and do not become invasive. Physicians do not want to over treat DCIS and cause unnecessary side effects if the DCIS does not become aggressive. However, chloroquine is a relatively safe treatment that does not have the severe side effects of typical chemotherapy.

"I think the most exciting thing is that we are able to offer women a new clinical trial using a well tolerated therapy in a new way to help prevent the development of invasive breast cancer and hopefully, ultimately, it will keep them from needing any additional treatment or surgery," says Edmiston. "We look forward to a future where all breast cancer can be prevented or destroyed."


'/>"/>

Contact: Marjorie Musick
mmusick@gmu.edu
703-993-8781
George Mason University
Source:Eurekalert

Related medicine news :

1. New Heart Pump Shows Promise in Trial
2. Trial to Test Gene Therapy for Angina in Women
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. MDS Pharma Services Wins Award for Management of Global Malaria Trial
7. New Ovarian Cancer Drug Trial Under Way
8. Study Questions Dead-End Cancer Clinical Trials
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
11. Clinical trials present better alternatives for dialysis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
(Date:3/28/2017)... ... 2017 , ... Calibration, qualification, and the appropriate level of ... GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled “ ... requirements are explained. The challenge is to determine how to put the ...
(Date:3/28/2017)... Billerica, MA (PRWEB) , ... March 28, 2017 ... ... instrument for direct measurement of corrosive ions found in power plant water and ... plant components such as turbines and boilers, leading to extensive maintenance and unplanned ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... New York , March 28, 2017 ... a largely consolidated vendor landscape, with the top three ... Agilent Technologies accounting for a significant 49% of the ... a recent report. The vendor landscape is intensely competitive ... share in the overall market. These factors have restricted ...
(Date:3/28/2017)... March 28, 2017 This ... these four stocks: The Medicines Co. (NASDAQ: MDCO), ... (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: ... Generic Drugs space which is governed by the ... drivers for the industry are wholesalers, retailers, pharmacies, ...
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary of ... the company,s board of directors: ... Mr. Gabrieli will serve as chairman of the board of ... chief commercial officer of Forest Laboratories. ... Partners. "We are excited to announce ...
Breaking Medicine Technology: